Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
162 hedge funds and large institutions have $305M invested in Antares Pharma, Inc. in 2021 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 58 increasing their positions, 56 reducing their positions, and 24 closing their positions.
242% more call options, than puts
Call options by funds: $482K | Put options by funds: $141K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
4% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 56
2% more capital invested
Capital invested by funds: $300M → $305M (+$4.99M)
5% less funds holding
Funds holding: 170 → 162 (-8)
21% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$7.11M |
| 2 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$3.6M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$3.09M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.8M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$2.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$3.17M |
| 2 |
VCM
Venator Capital Management
Toronto,
Ontario, Canada
|
-$2.56M |
| 3 |
Two Sigma Investments
New York
|
-$2.19M |
| 4 |
Two Sigma Advisers
New York
|
-$1.76M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1.6M |
ATRS Hedge Fund Activity: Q4 2021 in Review
162 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q4 2021, worth a combined $305M — up 1.7% from $300M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of ATRS and 19 opened new positions — a net loss of 5 holders — while 56 trimmed existing stakes and 58 added.
The largest buyer was Stonepine Capital Management, adding an estimated $7.11M. The largest seller was Assenagon Asset Management, cutting an estimated $3.17M.
- 162 institutional investors held Antares Pharma, Inc. (ATRS) as of Q4 2021, down from 170 in Q3 2021.
- Funds reported $305M of Antares Pharma, Inc. stock for Q4 2021, up 1.7% quarter-over-quarter.
- 19 funds opened new Antares Pharma, Inc. positions in Q4 2021 and 24 closed out, a net change of -5 holders.
- The largest Antares Pharma, Inc. buyer in Q4 2021 was Stonepine Capital Management, an estimated $7.11M added.
- The largest Antares Pharma, Inc. seller in Q4 2021 was Assenagon Asset Management, an estimated $3.17M sold.
Based on aggregated 13F filings for Q4 2021.